Latest News
BrightFocus President and CEO Stacy Pagos Haller spoke with WebMD about the latest breakthroughs in macular degeneration research.
BrightFocus Foundation, in partnership with three other global vision loss advocacy organizations, has declared Dec. 5 as World Geographic Atrophy Day.
A potential drug rooted in initial grant funding from BrightFocus Foundation to Dr. Ilyas Washington gives hope to those suffering from Stargardt disease, a genetic form of macular degeneration.
Vision scientists from across the globe will convene at BrightFocus Foundation’s second Macular Fast Track program on October 23 in Torremolinos, Spain. The immersive workshop, which serves as the pre-symposium of the International Symposium on Retinal Degeneration (RD2023), trains promising graduate students, postdoctoral fellows, and other early-career scientists focused on vision research to help speed progress toward a cure for macular degeneration.
Researchers have successfully demonstrated that hagfish slime proteins can accurately replicate membranes in the human eye.
The FDA has approved a new dosing regimen for Eylea, an injectable drug to treat degenerative eye diseases such as wet age-related macular degeneration. This means people taking the drug may need these eye injections less frequently.
Taking a unique approach to better diagnose and treat one of the world’s leading causes of blindness, a researcher from the University of Canberra in Australia has received a $500,000 boost for his three-year project, thanks to a grant from BrightFocus Foundation’s Macular Degeneration Research program.
Izervay, a second drug to treat the advanced and severe form of dry macular degeneration known as geographic atrophy, has received full FDA approval, opening another avenue of hope for people with this vision-stealing condition.
For the first time, a research team has created laboratory-grown cone photoreceptor cells that respond to light, unlocking a potential new way to treat macular degeneration.
A BrightFocus-funded research team has identified how an FDA-approved antioxidant may be used to help prevent age-related macular degeneration in people with certain genetic risk factors for the disease.
